Journal Article Review Epublish
PubMed: 40511456 DOI: 10.3389/fpsyt.2025.1589663
Abnormalities of lipid metabolism in the progression and treatment of depression.
Front Psychiatry 16:1589663
Authors: Xinchi Luan, Xuezhe Wang, Ying Shi, Xinyi Zhang, Yilin Wang, Miao Zhou, Zhaoyi Wu, Zijiao Liu, Xiaoxuan Li, Lihua Zhang, Tianyi Shao, Ruolan Chen, Xianming Chu, Hongyun Wei
Affiliations
- Department of Oncology, Key Laboratory of Cancer Molecular and Translational Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Gastroenterology, the affiliated hospital of Qingdao university, Qingdao, Shandong, China. Center of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- School of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
- Department of Gastroenterology, the affiliated hospital of Qingdao university, Qingdao, Shandong, China.
- Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Abstract
Depression represents a global health challenge with complex etiology and significant societal impact. Recent advancements reveal a critical role of lipid metabolism dysregulation in the pathogenesis and severity of depressive disorders. This review elucidates the impact of lipid imbalance on depression highlighting how dyslipidemia not only makes individuals prone to depression but also exacerbates the progression of depression (including the occurrence of some comorbidities of depression). On this basis, we have summarized that abnormal lipid metabolism may serve as a diagnostic and therapeutic target for depression. We discuss the perturbation of lipid homeostasis in depression, marked by altered triglycerides and high-density lipoprotein levels, and the potential of these lipids as biomarkers for diagnostic precision and therapeutic efficacy. Special emphasis is placed on the molecular mechanisms where lipids influence neuronal function and stress responses, thereby affecting mood and cognitive outcomes. Furthermore, we explore the comorbidity of depression with other systemic illnesses, suggesting a shared lipid-mediated metabolic pathway. Given the integral role of lipids in neural architecture and signaling, targeting lipid metabolism could offer novel therapeutic avenues, enhancing neuroplasticity and potentially mitigating depressive symptoms. Our synthesis aims to pave the way for future investigations into lipid-centric strategies to combat depression, advocating for a metabolic reorientation in mental health therapeutics.
MeSH
Depression, Comorbidity, Dyslipidemias, Biomarkers, Therapeutics